Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921850 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT06921850 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 40 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 10 states.
The verdict
NCT06921850, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (17)
Other
- Hs0006 40326 - Berlin
- Hs0006 40747 - Mainz
- Hs0006 40625 - Warsaw
- Hs0006 40761 - Warsaw
- Hs0006 40095 - Wroclaw
- Hs0006 40845 - Wroclaw
Michigan
- Hs0006 50178 - Clarkston
- Hs0006 50710 - Fort Gratiot
- Hs0006 50711 - Troy
Arizona
- Hs0006 50175 - Phoenix
California
- Hs0006 50708 - Roseville
District of Columbia
- Hs0006 50707 - Washington D.C.
Florida
- Hs0006 50199 - Miami
New York
- Hs0006 50712 - Brooklyn
North Carolina
- Hs0006 50706 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2029-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06921850
The ClinicalTrials.gov registry entry for NCT06921850 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (93% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT06921850 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT06921850 about?
NCT06921850 is a clinical study titled "A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa". The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
What is the current status of trial NCT06921850?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2025-04-07. Estimated completion is 2029-03-06.
What conditions does trial NCT06921850 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06921850?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06921850?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921850 being conducted?
This trial has 17 study locations across Arizona, California, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.